The approval of novel agents, specifically blinatumomab (Blincyto) and CAR T-cell therapy, in the acute lymphoblastic leukemia (ALL) paradigm has led has to expanded options for pediatric, adolescent and young adult (AYA), and adult patients; however, ongoing trials are poised to keep moving the field forward, said Joseph Wynne, MD.
A biologics license application has been submitted to the FDA for the rituximab (Rituxan) biosimilar ABP 798, according to the developers, Amgen and Allergan
Myeloma therapies continue to improve, and maybe one day there will be a cure, says one expert.
Minimal residual disease status could cause patients undue stress.
Nurses play a key role in treating patients with myeloma.
A majority of adult patients with β-thalassemia who require regular red blood cell (RBC) transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl) in the phase III BELIEVE trial.
CAR T-cell therapy is an emerging targeted therapy that has large potential for patients whose disease is relapsed or refractory.
The combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) elicited a 100% overall response rate (ORR) in patients with relapsed indolent non-Hodgkin lymphoma (NHL) that was refractory to rituximab (Rituxan), according to findings of a single-arm, phase I/II trial presented at the 2019 ASH Annual Meeting.
Steroid use while cytokine release syndrome (CRS) and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to abatacept (Orencia) to prevent moderate or severe acute graft-versus-host disease (GvHD) in patients who underwent a hematopoietic stem cell transplant and are not related to their donors, according to Bristol-Myers Squibb, the manufacturer of the drug.
JAK inhibitors have been the standard of care for patients with myelofibrosis, but now patients need novel agents to help.
New approvals in the treatment of patients with myeloma has led to the question of what sequencing of drugs will work best for patients.
The FDA has approved acalabrutinib for the treatment of adult patients with CLL or SLL.
The Food and Drug Administration granted accelerated approval to zanubrutinib for the treatment of relapsed and refractory mantle cell lymphoma.
Elderly patients with AML have long faced limited options for their treatment, but that is no longer the case. However, challenges still remain in the treatment of this patient population.
Precision medicine is sweeping across the cancer care spectrum, and now, experts have their sights set on applying it in MCL.
Any patient with cancer needs a caregiver through the treatment journey, but it's even more vital for patients with cancer undergoing the stem cell transplant process.
The FDA has granted an RMAT designation for an investigational CAR-T cell therapy used to treat patients with multiple myeloma.
Frahad Ravandi-Kashani, MD, had the chance to discuss the role of MRD in treating patients with hairy cell leukemia.
New research and techniques indicate an easier path forward for identifying hairy cell leukemia.
MRD can prove useful in the treatment of patients with hairy cell leukemia who relapsed.
For patients with hairy cell leukemia, it's complications after treatment that can be life-threatening.
At the 2019 Hairy Cell Leukemia Foundation Annual Conference new findings showed promise in the safety of vemurafenib to treat patients with hairy cell leukemia.
Chemotherapy is often associated with devastating toxicities, but moxetumomab pasudotox appears to be manageable based on the findings from a new trial.
A label update from the FDA has approved a sBLA for romiplostim to include data demonstrating sustained platelet responses in adults with ITP.
